HRP20161225T1 - Marker cjepivo za klasičnu svinjsku groznicu - Google Patents
Marker cjepivo za klasičnu svinjsku groznicu Download PDFInfo
- Publication number
- HRP20161225T1 HRP20161225T1 HRP20161225TT HRP20161225T HRP20161225T1 HR P20161225 T1 HRP20161225 T1 HR P20161225T1 HR P20161225T T HRP20161225T T HR P20161225TT HR P20161225 T HRP20161225 T HR P20161225T HR P20161225 T1 HRP20161225 T1 HR P20161225T1
- Authority
- HR
- Croatia
- Prior art keywords
- substitution
- amino acid
- marker vaccine
- swine fever
- vaccine according
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 15
- 239000003550 marker Substances 0.000 title claims 14
- 208000001726 Classical Swine Fever Diseases 0.000 title claims 3
- 238000006467 substitution reaction Methods 0.000 claims 18
- 150000001413 amino acids Chemical group 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 241000710777 Classical swine fever virus Species 0.000 claims 8
- 230000003612 virological effect Effects 0.000 claims 8
- 241000700605 Viruses Species 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 7
- 229940024606 amino acid Drugs 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000004458 analytical method Methods 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 101710125507 Integrase/recombinase Proteins 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 230000000405 serological effect Effects 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 241000700199 Cavia porcellus Species 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 101710132593 Protein E2 Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Marker cjepivo za zaštitno liječenje klasične svinjske groznice sadrži modificirani živi oslabljeni virus svinjske groznice, naznačeno time što virusni aminokiselinski slijed TAV-epitopa proteina E2 obuhvaća slijed različit od divljeg tipa virusa klasične svinjske groznice, tako da aminokiselinski slijed pokazuje najmanje jednu od sljedećih supstitucija u odnosu na C-soj „Riems“ virusa:
- supstituciju aminokiseline 830 valinom,
- supstituciju aminokiseline 833 serinom,
- supstituciju aminokiseline 839 glicinom.
2. Marker cjepivo u skladu s prethodnim patentnim zahtjevom, naznačeno time što modificirani virus ne izražava rekombinantne sljedove nukleinske kiseline.
3. Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što virusni slijed nukleotida izražava jednu ili više od sljedećih supstitucija u odnosu na C-soj „Riems“ virusa:
- supstituciju na mjestu nukleotida 2862 u T,
- supstituciju na mjestu nukleotida 2870 u T,
- supstituciju na mjestu nukleotida 2889 u G.
4. Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što virusni aminokiselinski slijed izražava jednu ili više od sljedećih supstitucija u odnosu na C-soj „Riems“ virusa:
- supstituciju aminokiseline 426; u proteinu ERNS; valinom,
- supstituciju aminokiseline 576; u proteinu E1; histidinom;
- supstituciju aminokiseline 583; u proteinu E1; glutaminskom kiselinom;
- supstituciju aminokiseline 951; u proteinu E2; izoleucinom.
5. Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što virusni slijed nukleotida izražava jednu ili više od sljedećih supstitucija u odnosu na C-soj „Riems“ virusa:
- supstituciju na mjestu nukleotida 1649 u G,
- supstituciju na mjestu nukleotida 2099 u C,
- supstituciju na mjestu nukleotida 2122 u G,
- supstituciju na mjestu nukleotida 3225 u T.
6. Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što virusni aminokiselinski slijed TAV-epitopa sadrži slijed u skladu sa SEQ ID NO. 3 ili SEQ ID NO. 4.
7. Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što virusni slijed nukleotida sadrži slijed u skladu sa SEQ ID NO. 1.
8. Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što se subjekti tretirani cjepivom mogu razlikovati od subjekata zaraženih virusom svinjske groznice povezanim s bolešću analiziranjem biološkog uzorka dobivenog od navedenih subjekata koristeći serološke i/ili genomske analitičke metode.
9. Marker cjepivo skladu s prethodnim patentnim zahtjevom, naznačeno time što je genomska analitička metoda temeljena na lančanoj reakciji polimeraze (PCR), poželjno PCR u stvarnom vremenu, gdje se koriste početnice i/ili sonde koje prepoznaju bilo modificirani i/ili s bolešću povezani virusni slijed nukleotida.
10. Marker cjepivo skladu s patentnim zahtjevom 8, naznačeno time što je serološka analitička metoda temeljena na enzimskom imunoodređivanju (EIA), poželjno kompetitivnom enzimom-obilježenom imunokemijskom određivanju (ELISA), pri čemu se koriste protutijela koja se specifično vežu za bilo modificirani i/ili s bolešću povezani TAV-epitop.
11. Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, koje se može dobiti stvaranjem virusnih inačica koje izbjegavaju imunosni sustav virusnog soja povezanog s bolešću ili drugog poznatog soja virusa svinjske groznice, primjenom pritiska protutijelima.
12. Metoda za proizvodnju modificiranog soja živog oslabljenog virusa klasične svinjske groznice, poželjno u skladu s bilo kojim od patentnih zahtjeva 1 do 11, obuhvaća stvaranje inačica koje izbjegavaju imunosni sustav virusnog soja povezanog s bolešću ili drugog poznatog soja virusa svinjske groznice, primjenom pritiska protutijelima.
13. Metoda u skladu s patentnim zahtjevom 12, naznačena time što metoda obuhvaća:
- višestruku pasažu stanica, poželjno embrionskih stanica bubrega zamorca, zaraženih virusom svinjske groznice povezanim s bolešću u staničnoj kulturi, i
- istovremenu primjenu protutijela prema TAV-epitopu proteina E2 virusa svinjske groznice povezanog s bolešću i/ili poliklonskog CTAVSPTTLRTEVVK-peptidom imuniziranog zečjeg seruma.
14. Farmaceutski sastav sadrži marker cjepivo u skladu s bilo kojim od patentnih zahtjeva 1 do 11 s farmaceutski prihvatljivim nosačem.
15. Marker cjepivo u skladu s bilo kojim od patentnih zahtjeva 1 do 11 za uporabu kao lijek u zaštitnom liječenju (cijepljenju) klasične svinjske groznice, poželjno putem intramuskularne injekcije ili oralnom primjenom.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10075207 | 2010-05-18 | ||
| EP10075205 | 2010-05-18 | ||
| EP10075206 | 2010-05-18 | ||
| DE102010017006 | 2010-05-18 | ||
| EP10075760 | 2010-12-17 | ||
| EP10075759 | 2010-12-17 | ||
| EP11159207 | 2011-03-22 | ||
| PCT/EP2011/002624 WO2011144360A1 (en) | 2010-05-18 | 2011-05-18 | Marker vaccine for classical swine fever |
| EP11724548.0A EP2571519B1 (en) | 2010-05-18 | 2011-05-18 | Marker vaccine for classical swine fever |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161225T1 true HRP20161225T1 (hr) | 2016-12-02 |
Family
ID=44461927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161225TT HRP20161225T1 (hr) | 2010-05-18 | 2016-09-26 | Marker cjepivo za klasičnu svinjsku groznicu |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9315873B2 (hr) |
| EP (1) | EP2571519B1 (hr) |
| KR (1) | KR101845571B1 (hr) |
| CN (1) | CN102905725B (hr) |
| BR (1) | BR112012029145B8 (hr) |
| CA (1) | CA2801897C (hr) |
| CY (1) | CY1118060T1 (hr) |
| DK (1) | DK2571519T3 (hr) |
| EA (1) | EA031518B1 (hr) |
| ES (1) | ES2593965T3 (hr) |
| HR (1) | HRP20161225T1 (hr) |
| HU (1) | HUE029385T2 (hr) |
| MX (1) | MX337048B (hr) |
| PL (1) | PL2571519T3 (hr) |
| PT (1) | PT2571519T (hr) |
| RS (1) | RS55214B1 (hr) |
| SI (1) | SI2571519T1 (hr) |
| WO (1) | WO2011144360A1 (hr) |
| ZA (1) | ZA201208194B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103159858B (zh) * | 2013-02-26 | 2014-06-04 | 中国农业科学院上海兽医研究所 | 猪瘟分支肽及其应用 |
| WO2015177369A1 (en) * | 2014-05-23 | 2015-11-26 | Boehringer Ingelheim Vetmedica Gmbh | Recombinant classical swine fever virus (csfv) comprising substitution in the tav epitope of the e2 protein |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180109B1 (en) * | 1994-06-17 | 2001-01-30 | Instituut Voor Dierhouderij En Diergezondheid | Nucleotide and polypeptide sequences of pestivirus strains |
| US8846055B2 (en) * | 2006-05-30 | 2014-09-30 | The United States Of America, As Represented By The Secretary Of Agriculture | Virulence determinant within the E2 structural glycoprotein of classical swine fever virus |
| US8133495B2 (en) * | 2007-05-22 | 2012-03-13 | The United States Of America As Represented By The Secretary Of Agriculture | Live attenuated antigenically marked classical swine fever virus |
| EP2202298A1 (en) * | 2008-12-23 | 2010-06-30 | Stichting Dienst Landbouwkundig Onderzoek | Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV |
-
2011
- 2011-05-18 US US13/698,580 patent/US9315873B2/en active Active
- 2011-05-18 PL PL11724548T patent/PL2571519T3/pl unknown
- 2011-05-18 ES ES11724548.0T patent/ES2593965T3/es active Active
- 2011-05-18 CN CN201180024834.0A patent/CN102905725B/zh active Active
- 2011-05-18 CA CA2801897A patent/CA2801897C/en active Active
- 2011-05-18 SI SI201130975A patent/SI2571519T1/sl unknown
- 2011-05-18 HU HUE11724548A patent/HUE029385T2/en unknown
- 2011-05-18 DK DK11724548.0T patent/DK2571519T3/en active
- 2011-05-18 PT PT117245480T patent/PT2571519T/pt unknown
- 2011-05-18 KR KR1020127032927A patent/KR101845571B1/ko active IP Right Grant
- 2011-05-18 WO PCT/EP2011/002624 patent/WO2011144360A1/en active Application Filing
- 2011-05-18 RS RS20160807A patent/RS55214B1/sr unknown
- 2011-05-18 BR BR112012029145A patent/BR112012029145B8/pt active IP Right Grant
- 2011-05-18 EP EP11724548.0A patent/EP2571519B1/en active Active
- 2011-05-18 MX MX2012013419A patent/MX337048B/es active IP Right Grant
- 2011-05-18 EA EA201270794A patent/EA031518B1/ru unknown
-
2012
- 2012-10-31 ZA ZA2012/08194A patent/ZA201208194B/en unknown
-
2016
- 2016-09-26 HR HRP20161225TT patent/HRP20161225T1/hr unknown
- 2016-09-27 CY CY20161100960T patent/CY1118060T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012029145A2 (pt) | 2020-07-07 |
| ES2593965T3 (es) | 2016-12-14 |
| US9315873B2 (en) | 2016-04-19 |
| CN102905725A (zh) | 2013-01-30 |
| ZA201208194B (en) | 2014-01-29 |
| SI2571519T1 (sl) | 2017-01-31 |
| DK2571519T3 (en) | 2016-10-17 |
| CA2801897C (en) | 2019-01-15 |
| US20130129762A1 (en) | 2013-05-23 |
| EP2571519B1 (en) | 2016-06-29 |
| EA031518B1 (ru) | 2019-01-31 |
| KR101845571B1 (ko) | 2018-04-04 |
| MX337048B (es) | 2016-02-11 |
| PT2571519T (pt) | 2016-10-03 |
| PL2571519T3 (pl) | 2017-07-31 |
| HUE029385T2 (en) | 2017-02-28 |
| KR20130109008A (ko) | 2013-10-07 |
| RS55214B1 (sr) | 2017-02-28 |
| BR112012029145B8 (pt) | 2022-03-08 |
| CN102905725B (zh) | 2016-01-20 |
| EP2571519A1 (en) | 2013-03-27 |
| EA201270794A1 (ru) | 2013-04-30 |
| CA2801897A1 (en) | 2011-11-24 |
| MX2012013419A (es) | 2013-01-28 |
| WO2011144360A1 (en) | 2011-11-24 |
| BR112012029145B1 (pt) | 2021-09-14 |
| EA201270794A8 (ru) | 2017-10-31 |
| CY1118060T1 (el) | 2017-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andrews et al. | Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory B cell responses to influenza hemagglutinin | |
| Schnee et al. | An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs | |
| Poole et al. | Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments | |
| Chang et al. | Identification of neutralizing monoclonal antibodies targeting novel conformational epitopes of the porcine epidemic diarrhoea virus spike protein | |
| BR112014030797A2 (pt) | epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo | |
| JP2010539162A5 (hr) | ||
| BR112012003064B8 (pt) | anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo | |
| Luo et al. | Absence of anti-hypocretin receptor 2 autoantibodies in post pandemrix narcolepsy cases | |
| DK1709067T3 (da) | Vacciner med underenhed af Lawsonia intracellularis | |
| JP2010539161A5 (hr) | ||
| JP2022546046A (ja) | 修飾された環状ｒｎａ及びその使用法 | |
| JP2009529917A5 (hr) | ||
| CN113354717B (zh) | 一种新冠病毒SARS-CoV-2广谱多肽抗原及其特异性中和抗体和应用 | |
| Jiang et al. | A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge | |
| KR20180038261A (ko) | H7n9 조류 인플루엔자 바이러스 검출을 위한 효소면역 측정키트 | |
| JP2019504107A5 (hr) | ||
| RU2016133598A (ru) | Композиция микобактериального антигена | |
| Zhang et al. | Mapping the immunodominance landscape of SARS-CoV-2 spike protein for the design of vaccines against COVID-19 | |
| Laitinen et al. | New Coxsackievirus 2Apro and 3Cpro protease antibodies for virus detection and discovery of pathogenic mechanisms | |
| HRP20161225T1 (hr) | Marker cjepivo za klasičnu svinjsku groznicu | |
| Aparicio et al. | Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses | |
| Arikata et al. | Memory immune responses against pandemic (h1n1) 2009 influenza virus induced by a whole particle vaccine in cynomolgus monkeys carrying mafa-A1* 052∶ 02 | |
| US20220125911A1 (en) | Paramyxovirus and uses thereof | |
| HUE034632T2 (en) | Improved vaccine diagnostics | |
| TW201938578A (zh) | 腸病毒疫苗 |